Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience

OBJECTIVE:To evaluate hematological, cytogenetic and molecular responses as well as the overall, progression-free and event-free survivals of chronic myeloid leukemia patients treated with a third tyrosine kinase inhibitor after failing to respond to imatinib and nilotinib/dasatinib.METHODS:Bone mar...

Full description

Bibliographic Details
Main Authors: Beatriz Felicio Ribeiro, Eliana C.M. Miranda, Dulcinéia Martins de Albuquerque, Márcia T. Delamain, Gislaine Oliveira-Duarte, Maria Helena Almeida, Bruna Vergílio, Rosana Antunes da Silveira, Vagner Oliveira-Duarte, Irene Lorand-Metze, Carmino A. De Souza, Katia B.B. Pagnano
Format: Article
Language:English
Published: Elsevier España 2015-08-01
Series:Clinics
Subjects:
CML
Dasatinib
Nilotinib
Third-line TKI treatment
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322015000800550&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322015000800550&lng=en&tlng=en

Similar Items